Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation  

作　　者：Wattana Leowattana Tawithep Leowattana Pathomthep Leowattana 

机构地区：[1]Department of Clinical Tropical Medicine,Faculty of Tropical Medicine,Mahidol University,Bangkok 10400,Thailand [2]Department of Medicine,Faculty of Medicine,Srinakharinwirot University,Bangkok 10110,Thailand

出　　处：《World Journal of Clinical Cases》2022年第27期9588-9601,共14页世界临床病例杂志

摘　　要：Patient-specific human-induced pluripotent stem cell-derived atrial cardiomyocytes(hiPSC-aCMs) may be produced,genome-edited,and differentiated into multiple cell types for regenerative medicine,disease modeling,drug testing,toxicity screening,and three-dimensional tissue fabrication.There is presently no complete model of atrial fibrillation(AF) available for studying human pharmacological responses and evaluating the toxicity of potential medication candidates.It has been demonstrated that hiPSC-aCMs can replicate the electrophysiological disease phenotype and genotype of AF.The hiPSC-aCMs,however,are immature and do not reflect the maturity of a CMs in the native myocardium.Numerous laboratories utilize a variety of methodologies and procedures to improve and promote a CM maturation,including electrical stimulation,culture duration,biophysical signals,and changes in metabolic variables.This review covers the current methods being explored for use in the maturation of patient-specific hiPSC-aCMs and their application towards a personalized approach to the pharmacologic therapy of AF.

关 键 词：Atrial fibrillation Human-induced pluripotent stem cell-derived atrial cardiomyocytes Disease modeling Maturation Pharmacologic response Personalized medicine 

分 类 号：R541.75[医药卫生—心血管疾病]